KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Work In Process (2016 - 2024)

Historic Work In Process for Nektar Therapeutics (NKTR) over the last 12 years, with Q2 2024 value amounting to $10.6 million.

  • Nektar Therapeutics' Work In Process changed N/A to $10.6 million in Q2 2024 from the same period last year, while for Jun 2024 it was $10.6 million, marking a year-over-year change of. This contributed to the annual value of $12.9 million for FY2023, which is 1982.51% up from last year.
  • Per Nektar Therapeutics' latest filing, its Work In Process stood at $10.6 million for Q2 2024.
  • Nektar Therapeutics' 5-year Work In Process high stood at $12.9 million for Q4 2023, and its period low was $10.0 million during Q1 2024.
  • Over the past 3 years, Nektar Therapeutics' median Work In Process value was $10.7 million (recorded in 2022), while the average stood at $11.3 million.
  • Examining YoY changes over the last 5 years, Nektar Therapeutics' Work In Process showed a top increase of 1982.51% in 2023 and a maximum decrease of 1982.51% in 2023.
  • Nektar Therapeutics' Work In Process (Quarter) stood at $10.7 million in 2022, then increased by 19.83% to $12.9 million in 2023, then fell by 17.78% to $10.6 million in 2024.
  • Its Work In Process stands at $10.6 million for Q2 2024, versus $10.0 million for Q1 2024 and $12.9 million for Q4 2023.